BiondVax Pharmaceuticals Ltd. Stock Price, News & Analysis

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced the closure of a public offering of 4,144,068 American Depositary Shares (ADSs) at $2.36 each, raising approximately $9.8 million in gross proceeds. The funds will support the company's nanosized antibody (NanoAb) development program in collaboration with the Max Planck Institute. CEO Amir Reichman highlighted the significance of this funding for advancing innovative therapies. The offering was conducted under a shelf registration statement with the SEC, and Aegis Capital Corp. served as the sole book-running manager.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced the approval of all resolutions at its Annual General Meeting, including the election of Jay Green to the Board of Directors. Green, who has extensive experience in finance and operations within the vaccine sector, previously served as CFO of GlaxoSmithKline's global vaccines business. His addition is seen as a strategic move to enhance the company's R&D efforts, particularly around their promising nanosized antibody (NanoAb) program. Meanwhile, Isaac Devash has retired from the board after significant contributions.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced a public offering of 3,813,560 American Depositary Shares (ADSs) priced at $2.36 each, aiming for gross proceeds of approximately $9.0 million. The funds will advance its nanosized antibody development program and support general corporate purposes. Closing is expected on December 29, 2021, with a 45-day option for underwriters to purchase additional ADSs, potentially raising proceeds to $9.8 million. Aegis Capital Corp. is the sole book-running manager, with the offering under a shelf registration statement.

BiondVax Pharmaceuticals (Nasdaq: BVXV) announced an underwritten public offering of its American Depositary Shares (ADSs) on December 23, 2021. The company signed agreements with the Max Planck Society and University Medical Center Göttingen to develop nanosized antibodies (NanoAbs) aimed at neutralizing all COVID-19 variants, including Delta and Omicron. Proceeds from the offering will advance the NanoAbs program and cover general corporate purposes. Aegis Capital Corp. is the book-running manager for the offering, which is subject to market conditions.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced strategic agreements with the Max Planck Society and University Medical Center Göttingen to develop innovative COVID-19 nanosized antibodies (NanoAbs). These NanoAbs, exhibiting superior affinity and stability, could neutralize SARS-COV-2 at lower concentrations than current therapies. The collaboration aims to also address other major diseases, including psoriasis and asthma, leveraging the competitive advantages of NanoAbs. Preclinical studies are planned for 2022, with initial clinical results anticipated in 2023.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported its Q3 2021 financial results, reflecting a significant decrease in R&D expenses to NIS 2.0 million ($0.6 million), down from NIS 12.6 million in Q3 2020. Marketing and administrative costs also fell to NIS 6.2 million ($1.9 million), contributing to total operating expenses of NIS 8.2 million ($2.5 million), compared to NIS 20.0 million in the prior year. The company is collaborating with Max Planck Society to develop innovative VHH-antibodies aimed at addressing COVID-19 and other diseases. Cash and equivalents were NIS 34.6 million ($10.7 million) as of September 30, 2021.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its Annual General Meeting (AGM) scheduled for December 27, 2021, in Tel Aviv, Israel. Key resolutions include the election of Jay Green to the Board of Directors. BiondVax has formed a strategic collaboration with the Max Planck Institute for the development of innovative VHH-antibody therapies, focusing on COVID-19 and other diseases. Preparations for manufacturing these antibodies have commenced at its GMP facility in Jerusalem. The AGM will also cover auditor appointments and the adoption of an updated compensation policy.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference on Nov. 15, 2021, at 10:30 am ET. The biopharmaceutical company specializes in developing innovative products for infectious disease prevention and treatment. BiondVax has conducted eight clinical trials, including a Phase 3 trial with 12,400 participants. Investors interested in attending can register at H.C. Wainwright's website.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a strategic collaboration with the Max Planck Society and the University Medical Center Göttingen in Germany. The 5-year partnership will allow BiondVax to license novel VHH antibodies, which exhibit enhanced efficacy against COVID-19 variants at lower concentrations than existing treatments. The collaboration aims to address various diseases and will leverage BiondVax's manufacturing capabilities in Jerusalem. Definitive agreements are expected within 90 days, although execution is not guaranteed.